• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 12, 2022 at 10:52: AM
via AstraZeneca and Daiichi Sankyo have reported updated data from the Phase I TROPION-PanTumor01 clinical trial, where their datopotamab deruxtecan (Dato-DXd) showed to offer encouraging responses in heavily pretreated metastatic triple-negative breast cancer (TNBC) patients.

article source
 




Top Bottom
Back
Quote